The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b/2, open-label study to evaluate the safety and tolerability of MEDI6469 in combination with immune therapeutic agents or therapeutic mAbs in patients with selected advanced solid tumors or aggressive B-cell lymphomas.
 
John D. Powderly
Employment - BioCytics
Leadership - BioCytics
Stock and Other Ownership Interests - BioCytics
Honoraria - BioCytics
Consulting or Advisory Role - Amplimmune; AstraZeneca; Bristol-Myers Squibb; Genentech; Merck
Speakers' Bureau - Bristol-Myers Squibb; Merck
Research Funding - Amplimmune; AstraZeneca; Bristol-Myers Squibb; EMD Serono; Genentech; ImClone Systems; Incyte; Macrogenics
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Martin Gutierrez
Research Funding - Abbvie (Inst); Acceleron Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Esanex (Inst); Gilead Sciences (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); MedImmune (Inst); Novartis (Inst); Rexahn Pharmaceuticals (Inst); TG Therapeutics (Inst)
 
Ding Wang
Research Funding - MedImmune (Inst)
 
Young Kwang Chae
Research Funding - MedImmune (Inst)
 
Daruka Mahadevan
Honoraria - Janssen Biotech
Speakers' Bureau - Janssen Biotech
Research Funding - MedImmune (Inst)
Travel, Accommodations, Expenses - Janssen Biotech
 
Fadi S. Braiteh
Employment - US Oncology
Stock and Other Ownership Interests - Celgene; Insys Therapeutics
Honoraria - Amgen; BIND Therapeutics; Caris Life Sciences; Dendreon; Foundation Medicine; Incyte; Insys Therapeutics; MolecularHealth; Novartis; Pfizer; Salarius Pharmaceuticals; Sanofi
Consulting or Advisory Role - Amgen; BIND Therapeutics; Caris Life Sciences; Dendreon; Foundation Medicine; Incyte; Insys Therapeutics; MolecularHealth; Novartis; Pfizer; Saladax Biomedical; Sanofi
Speakers' Bureau - Amgen; Bayer; Bristol-Myers Squibb; Caris Life Sciences; Celgene; Genomic Health; Incyte; Insys Therapeutics; Myriad Pharmaceuticals; Novartis; Pfizer; Sanofi
Research Funding - Abbvie (Inst); Active Biotech (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BIND Therapeutics (Inst); Biomarin (Inst); bioTheranostics (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Caris Life Sciences (Inst); Celgene (Inst); Cell Therapeutics (Inst); Daiichi Sankyo (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Foundation Medicine (Inst); Genomic Health (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); HERON (Inst); ImClone Systems (Inst); Incyte (Inst); Insys Therapeutics (Inst); Janssen (Inst); Lilly (Inst); MEI Pharma (Inst); Merrimack (Inst); Millennium (Inst); MolecularHealth (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Plexxikon (Inst); PSMA Development Company (Inst); Roche/Genentech (Inst); Saladax Biomedical (Inst); Saladax Biomedical (Inst); Sanofi (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Viamet Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Caris Life Sciences; Celgene; Foundation Medicine; Genomic Health; Gilead Sciences; HERON; Incyte; Insys Therapeutics; Lilly; MolecularHealth; Pfizer; Roche/Genentech; Saladax Biomedical; Sanofi
 
Bonnie S. Glisson
Research Funding - MedImmune (Inst); Stem CentRx (Inst)
 
Dongyue Fu
Employment - MedImmune
Stock and Other Ownership Interests - AstraZeneca
 
Michele Jordan
Stock and Other Ownership Interests - AstraZeneca
Travel, Accommodations, Expenses - LLC; MedImmune
 
Jennifer T. McDevitt
Employment - MedImmune
Stock and Other Ownership Interests - MedImmune
 
Mark C. Lanasa
Employment - MedImmune
Stock and Other Ownership Interests - AstraZeneca
Consulting or Advisory Role - Abbvie; Amgen; Genentech
Research Funding - Celgene (Inst)
 
Brendan D. Curti
Honoraria - Prometheus
Research Funding - Bristol-Myers Squibb (Inst); MedImmune (Inst); Prometheus (Inst)
Travel, Accommodations, Expenses - Agonox; Prometheus